Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

Phase 3 Completed 223 enrolled University of Miami

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

Timeline

Start: 2022-05-01
Primary completion: 2023-05-01
Completion: 2023-05-01

Publications

Rizzo MG, Costello JP 2nd, Constantinescu DS, Samineni AV, Moore MR, Shittu AT, Tabibi O, Osman BM, Fiala RS, D'Apuzzo MR, Hernandez VH. Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial. J Arthroplasty. 2026 Jul;41(7):1954-1959. doi: 10.1016/j.arth.2025.10.052. Epub 2025 Oct 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ketorolac	Other / unclassified	15 mg	Intravenous
Subject	Meloxicam	Small molecule	30 mg	Intravenous

Indications

No indication recorded.